

III. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
佐竹 涉 戸田 達史	神経疾患と遺伝子	飯森真喜雄 内山 真一 片山 容一 岸本 年史 水澤 英洋	神経・精神疾患診療マニュアル	日本医師会	東京	2013	S38-S39
服部 信孝	パーキンソン病の遺伝学と遺伝子診断の手順	山本 光利	GPレジデントのためのパーキンソン病テキストブック	アルタ出版	東京	2012	74-84
今居 譲 服部 信孝	第1章 microRNA 診断 神経変性疾患に関与する miRNA とその臨床応用への可能性	尾崎 充彦 黒田 雅彦 落谷 孝広	臨床・創薬利用が見えてきた microRNA, 遺伝子医学 MOOK (1349-2527) 23号	メディカルドゥ	東京	2012	44-47
村田 美穂	パーキンソン病の診断と治療 パーキンソン病治療薬：L-dopa と関連薬剤	山本 光利	GP・レジデントのためのパーキンソン病テキストブック	アルタ出版	東京	2012	111-119
村田 美穂		村田 美穂	やさしいパーキンソン病の自己管理 改訂版	医薬ジャーナル社	大阪	2012	

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Lynch TA, Lam le T, Man Nt, Kobayashi K, <u>Toda T</u> , Morris GE	Detection of the dystroglycanopathy protein, fukutin, using a new panel of site-specific monoclonal antibodies.	Biochem Biophys Res Commun	424	354-357	2012
Sharma M, Ioannidis JPA, Aasly JO, Brice A, Van Broeckhoven C, Annesi G, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris MF, Farrer M,	Large-scale replication and heterogeneity in Parkinson disease genetic loci.	Neurology	79	659-667	2012

Gispert S, Auburger G, Vilarino-Guell, Garraux G, Hadjigeorgiou GM, Hicks AA, <u>Hattori N</u> , Jeon BS, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok VCT, Jasinska-Myga B, Mellick GD, Morrison KE, Opala GM, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva EA, Ross OA, Stefanis L, Stockton J, Satake W, Silburn P, Theuns J, Tan EK, <u>Toda T</u> , Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Yueh KC, ZHAO YI, Gasser T, Maraganore DM, Krüger R					
Tsutsumi M, Kowa-Sugiyama H, Bolor H, Kogo H, Inagaki H, Ohye T, Yamada K, Taniguchi-Ikeda M, <u>Toda T</u> , Kurahashi H	Screening of genes involved in chromosome segregation during meiosis I: in vitro gene transfer to mouse fetal oocytes.	J Hum Genet	57	515-522	2012
Nakagawa N, Many H, <u>Toda T</u> , Endo T, Oka S	Human natural killer-1 sulfotransferase (HNK-1ST)-induced sulfate-transfer regulates laminin-binding glycans on α -dystroglycan.	J Biol Chem	287	30823-30832	2012
Shirafuji T, Kanda F, Sekiguchi K, Higuchi M, Yokosaki H, Tanaka K, Takahashi H, <u>Toda T</u>	Anti-Hu-associated paraneoplastic encephalomyelitis with esophageal small cell carcinoma.	Int Med	51	2423-2427	2012
Yu CC, Furukawa M, Kobayashi K, Shikishima C, Cha PC, Sese J, Sugawara H, Iwamoto K, Kato T, Ando J, <u>Toda T</u>	Genome-wide DNA methylation and gene expression analyses of monozygotic twins discordant for intelligence levels.	PLoS ONE	7	e47081	2012
Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Bertram L, Bozi M, Barcikowska M, Crosiers D, Clarke CE, Facheris MF, Farrer M, Garraux G, Gispert S, Auburger G, Vilarino-Güell C, Hadjigeorgiou GM, Hicks AA, <u>Hattori N</u> , Jeon BS, Jamrozik Z, Krygowska-Wajs A,	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants.	J Med Genet	49	721-726	2012

Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Libioulle C, <u>Murata M</u> , Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Meitnger T, Zimprich A, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Strom TM, Theuns J, Tan EK, <u>Toda T</u> , Tomiyama H, Uitti RJ, Van Broeckhoven C, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yomono HS, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEOPD consortium					
Popiel HA, Takeuchi T, Fujita H, Yamamoto K, Ito C, Yamane H, Muramatsu S, <u>Toda T</u> , Wada K, Nagai Y	Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.	PLoS One	7	e51069	2012
Ando J, Fujisawa KK, Shikishima C, Hiraishi K, Nozaki M, Yamagata S, Takahashi Y, Ozaki K, Suzuki K, Deno M, Sasaki S, <u>Toda T</u> , Kobayashi K, Sugimoto Y, Okada M, Kijima N, Ono Y, Yoshimura K, Kakihana S, Maekawa H, Kamakura T, Nonaka K, Kato N, Ooki S	Two cohort and three independent anonymous twin projects at the Keio Twin Research Center (KoTReC).	Twin Res Hum Genet	16	202-216	2013
Uenaka K, Kowa H, Sekiguchi K, Nagata K, Ohtsuka Y, Kanda F, <u>Toda T</u>	Myositis with antimitochondrial antibodies diagnosed by musculus rectus abdominis biopsy.	Muscle Nerve	47	766-768	2013
Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K,	Modeling Alzheimer's Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular A β and Differential Drug Responsiveness.	Cell Stem Cell	2	487-496	2013

Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H					
Popiel HA, Takeuchi T, Burke JR, Strittmatter WJ, <u>Toda T</u> , Wada K, Nagai Y	Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.	Neurotherapeutics	10	440-446	2013
Kanagawa M, Yu CC, Ito C, Fukada SI, Hozoji-Inada M, Chiyo T, Kuga A, Matsuo M, Sato K, Yamaguchi M, Ito T, Ohtsuka Y, Katanosaka Y, Miyagoe-Suzuki Y, Naruse K, Kobayashi K, Okada T, Takeda S, <u>Toda T</u>	Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.	Hum Mol Genet	22	3003-3015	2013
Ueda T, Seki T, Katanazaka K, Sekiguchi K, Kobayashi K, Kanda F, <u>Toda T</u>	A novel mutation in the C2 domain of protein kinase C gamma associated with spinocerebellar ataxia type 14.	J Neurol	260	1664-1666	2013
Mitsui J, Matsukawa T, Ishiura H, Fukuda Y, Ichikawa Y, Date H, Ahsan B, Nakahara Y, Momose Y, Takahashi Y, Iwata A, Goto J, Yamamoto Y, Komata M, Shirahige K, Hara K, Kakita A, Yamada M, Takahashi H, Onodera O, Nishizawa M, Takashima H, Kuwano R, Watanabe H, Ito M, Sobue G, Soma H, Yabe I, Sasaki H, Aoki M, Ishikawa K, Mizusawa H, Kanai K, Hattori T, Kuwabara S, Arai K, Koyano S, Kuroiwa Y, Hasegawa K, Yuasa T, Yasui K, Nakashima K, Ito H, Izumi Y, Kaji R, Kato T, Kusunoki S, Osaki Y, Horiuchi M, Kondo T, Murayama S, Hattori N, Yamamoto M, Murata M, Satake W, <u>Toda T</u> , Dürr A, Brice A, Filla A, Klockgether T, Wüllner U, Nicholson G, Gilman S, Shults CW, Tanner CM, Kukull WA, Lee VM, Masliah E, Low PA,	Mutations in COQ2 in familial and sporadic multiple-system atrophy.	N Engl J Med	369	233-244	2013

Sandroni P, Trojanowski JQ, Ozelius L, Foroud T, Tsuji S.					
Yasui N, Takaoka Y, Nishio H, Nurputra DK, Sekiguchi K, Hamaguchi H, Kowa H, Maeda E, Sugano A, Miura K, Sakaeda T, Kanda F, <u>Toda T.</u>	Molecular pathology of Sandhoff disease with p.Arg505Gln in HEXB: application of simulation analysis.	J Hum Genet	58	611-617	2013
Mizuta I, Takafuji K, Ando Y, Satake W, Kanagawa M, Kobayashi K, Nagamori S, Shinohara T, Ito C, Yamamoto M, Hattori N, Murata M, Kanai Y, Murayama S, Nakagawa M, <u>Toda T.</u>	YY1 binds to α -synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression.	J Hum Genet	58	711-719	2013
Ogaki K, Li Y, Takanashi M, Ishikawa K, Kobayashi T, Nonaka T, Hasegawa M, Kishi M, Yoshino H, Funayama M, Tsukamoto T, Shioya K, Yokochi M, Imai H, Sasaki R, Kokubo Y, Kuzuhara S, Motoi Y, Tomiyama H, <u>Hattori N</u>	Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTL, PSP, and CBS.	Parkinsonism Relat Disord	19	15-20	2013
Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, <u>Hattori N</u>	PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy.	Sci Rep	2	1002	2012
Ando M, Funayama M, Li Y, Kashihara K, Murakami Y, Ishizu N, Toyoda C, Noguchi K, Hashimoto T, Nakano N, Sasaki R, Kokubo Y, Kuzuhara S, Ogaki K, Yamashita C, Yoshino H, Hatano T, Tomiyama H, <u>Hattori N</u>	VPS35 mutation in Japanese patients with typical Parkinson's disease.	Mov Disord	27	1413-1417	2012
Ujiie S, Hatano T, Kubo S, Imai S, Sato S, Uchiyama T, Yagishita S, Hasegawa K, Kowa H, Sakai F, <u>Hattori N</u>	LRRK2 I2020T mutation is associated with tau pathology.	Parkinsonism Relat Disord	18	819-823	2012
<u>Hattori N</u> , Hasegawa K, Sakamoto T	Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.	J Clin Pharm Ther	37	571-577	2012
Ogaki K, Li Y, Atsuta N,	Analysis of C9orf72 repeat	Neurobiol Aging	33	2527.e11-6	2012

Tomiyama H, Funayama M, Watanabe H, Nakamura R, Yoshino H, Yato S, Tamura A, Naito Y, Taniguchi A, Fujita K, Izumi Y, Kaji R, <u>Hattori N</u> , Sobue G; Japanese Consortium for Amyotrophic Lateral Sclerosis research (JaCALS)	expansion in 563 Japanese patients with amyotrophic lateral sclerosis.				
Inoue Y, Uchimura N, Kuroda K, Hirata K, <u>Hattori N</u>	Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients.	Prog Neuropsychopharmacol Biol Psychiatry	36	251-257	2012
<u>Hattori N</u> , Fujimoto K, Kondo T, <u>Murata M</u> , Stacy M	Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys.	Patient Relat Outcome Meas	3	31-38	2012
Shimura H, Mizuno Y, <u>Hattori N</u>	Parkin and Parkinson disease.	Clin Chem	58	1260-1261	2012
Saiki S, Sato S, <u>Hattori N</u>	Molecular pathogenesis of Parkinson's disease: update.	J Neurol Neurosurg Psychiatry	83	430-436	2012
<u>Hattori N</u>	Autosomal dominant parkinsonism: its etiologies and differential diagnoses.	Parkinsonism Relat Disord	18 Suppl 1	S1-3	2012
Furusawa Y, Mukai Y, Kawazoe T, Sano T, Nakamura H, Sakamoto C, Iwata Y, Wakita M, Nakata Y, Kamiya K, Kobayashi Y, Sakamoto T, Takiyama Y, <u>Murata M</u> .	Long-term effect repeated lidocaine injections into the external oblique for upper camptocormia in Parkinson's disease.	Parkinsonism Relat Disord	19	350-354	2013
Mori-Yoshimura M, Oya Y, Hayashi YK, Noguchi S, Nishino I, <u>Murata M</u> .	Respiratory dysfunction in patients severely affected by GNE myopathy (distal myopathy with rimmed vacuoles)	Neuromuscul Disord	23	84-88	2013
Mori-Yoshimura M, Okuma A, Oya Y, Fujimura-Kiyono C, Matsuura K, Takemura A, Malicdan MC, Hayashi YK, Nonaka I, <u>Murata M</u> , Nishino I.	Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2.	Clin Neurosurg	114	678-683	2012
Yamamoto T, Chihara N, Mori-Yoshimura M, <u>Murata M</u> .	Videofluorographic detection of anti-muscle-specific kinase-positive myasthenia gravis.	Am J Otolaryngology	33	758-761	2012
Sato W, Tomita A, Ichikawa D, Lin Y, Kishida H, Miyake S, Ogawa M, Okamoto T, <u>Murata M</u> , Kuroiwa Y,	CCR2 ⁺ CCR5 ⁺ T Cells Produce Matrix Metalloproteinase-9 and Osteopontin in the Pathogenesis of Multiple	The Journal of Immunology		5057-5065	2012

Aranami T, Yamamura T.	Sclerosis.				
Kawazoe T, Araki M, Lin Y, Ogawa M, Okamoto T, Yamamura T, Wakakura M, <u>Murata M.</u>	New-Onset Type 1 Diabetes Mellitus and Anti-Aquaporin-4 Antibody Positive Optic Neuritis Associated with Type 1 Interferon Therapy for Chronic Hepatitis C.	Intern Med	51	2625-2629	2012
Mori-Yoshimura M, Monma K, Suzuki N, Aoki M, Kumamoto T, Tanaka K, Tomimitsu H, Nakano S, Sonoo M, Shimizu J, Sugie K, Nakamura H, Oya Y, Yukiko K, Hayashi, May Christine V, Malicdan, Noguchi s, <u>Murata M</u> , Nishino I.	Heterozygous UDP-GlcNAc 2-epimerase and N-acetylmannosamine kinase domain mutations in the GNE gene result in a less severe GNE myopathy phenotype compared to homozygous N-acetylmannosamine kinase domain mutations.	J Neurol Sci	318	100-105	2012
Kandori A, Yamamoto T, Sano Y, Oonuma M, Miyashita T, <u>Murata M</u> , and Sakoda S.	Simple Magnetic Swallowing Detection System.	IEEE Sensors Journal	12	805-811	2012
Furusawa Y, Mukai Y, Kobayashi Y, Sakamoto T, <u>Murata M.</u>	Role of the external oblique muscle in upper camptocormia for patients with Parkinson's disease.	Mov. Dis	27	802-803	2012
Yamamoto T, Ikeda K, Usui H, Miyamoto M, <u>Murata M.</u>	Validation of the Japanese translation of the Swallowing Disturbance Questionnaire in parkinson's disease patients.	Qual Life Res	21	1299-1303	2012
谷口 (池田) 真理子, 小林 千浩, 戸田 達史	MEDICAL TOPICS (第 42 回) 福山型筋ジストロフィーのスパライジング異常に対するアンチセンス治療 (解説)	THE LUNG-perspectives	20 巻 2 号	186-191	2012
戸田 達史, 谷口 (池田) 真理子, 小林 千浩	【遺伝性筋疾患の新たな治療戦略】 福山型筋ジストロフィーの新たな病態とアンチセンス療法	神経内科	76 巻 4 号	361-366	2012
佐竹 渉, 戸田 達史	【神経変性疾患のゲノム・遺伝学研究】 孤発性パーキンソン病のリスク遺伝子 (解説/特集)	Dementia Japan	26 巻 2 号	155-162	2012
戸田 達史, 谷口 (池田) 真理子, 小林 千浩	【神経筋疾患の分子標的治療開発】 福山型筋ジストロフィーの分子標的治療	BIO Clinica	27 巻 10 号	925-929	2012
大塚 喜久, 安井 直子, 関口 兼司, 古和 久朋, 西野 一三, 荻田 典生, 戸田 達史	骨格筋でのみアミロイドの沈着を確認しえたアミロイドーシスの 1 例	臨床神経学	52 巻 10 号	739-743	2012
谷口 (池田) 真理子, 小林千浩, 戸田 達史	福山型筋ジストロフィーの病的スパライジング異常と	実験医学	30 巻 6 号	950-953	2012

	アンチセンス療法				
谷口(池田)真理子, 戸田 達史	福山型先天性筋ジストロフィーの発症機序と治療戦略	細胞	44巻14号	598-602	2012
久我 敦, 戸田 達史	筋疾患の身体症状と認知症状	モダンフィジシャン (Modern Physician)	33巻1号	103-107	2012
戸田 達史	【次世代シーケンサーによる神経変性疾患の解析と展望】 パーソナルゲノム研究と神経疾患 overview	BRAIN and NERVE	65巻3号	227-234	2013
佐竹 渉, 戸田 達史	【ゲノム多様性と疾患】 ゲノム多様性と神経変性疾患	細胞	45巻3号	120-123	2013
戸田 達史	各種疾患 神経筋疾患 福山型筋ジストロフィーの分子病態と治療(解説)	Annual Review 神経	2013巻	238-245	2013
望月 秀樹, 戸田 達史, Wszolek Zbigniew K., 高橋 良輔, 坪井 義夫	パーキンソン病遺伝子に関する最新の知見	Frontiers in Parkinson Disease	6巻2号	61-67	2013
戸田 達史	パーキンソン病の臨床遺伝学	Mebio	30巻11号	17-22	2013
富施 敦仁, 深江 治郎, 服部 信孝	遺伝子工学からの恩恵 iPS 細胞の誕生と再生医療への応用	BIO Clinica	27	705-709	2012
舩山 学, 服部 信孝	遺伝子工学からの恩恵 連鎖解析、疾患遺伝子の探索 パーキンソン病遺伝子発見の経緯	BIO Clinica	27	294-297	2012
佐藤 栄人, 服部 信孝	【ミトコンドリア病-up to date】 神経疾患、老化とミトコンドリア異常 パーキンソン病	Clinical Neuroscience	30	1047-1050	2012
西岡 健弥, 服部 信孝	【神経科学新章! 脳疾患のバイオマーカーとオプトジェネティクス】 (第1部) Biomarker α -シヌクレインを中心としたパーキンソン病研究の現状と課題	実験医学	30	2563-2567	2012
舩山 学, 服部 信孝	【パーキンソン病医学・医療の最前線】 (第1部) 基礎編 遺伝子研究からわかったこと	Progress in Medicine	32	1167-1172	2012
山本 敏之, 臼井 晴美, 新庄 孝子, 市川 直美, 三好 智佳子, 村田 美穂	問診によるパーキンソン病患者の誤嚥の評価	嚥下医学		90-98	2012
村田 美穂, 北浦 円	パーキンソン病 高まるロードパ再評価の機運	クレデンシャル	49	14-20	2012
村田 美穂	高齢者パーキンソン病に対する治療の考え方	日本医事新報	7	78-82	2012
池田 謙輔, 岡本 智子, 山村 隆, 大澤 勲, 古寺 理恵, 村田 美穂	インターフェロン β -1b 長期治療中にネフローゼ症候群を合併した多発性硬化症の2例	臨床神経	53	19-23	2013
古澤 嘉彦, 村田 美穂	パーキンソン病と姿勢異常	Medical Practice	30	109-111	2013

IV. 研究成果の刊行物・別刷

Modeling Alzheimer's Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular A β and Differential Drug Responsiveness

Takayuki Kondo,^{1,2,7} Masashi Asai,^{7,9,10} Kayoko Tsukita,^{1,7} Yumiko Kutoku,¹¹ Yutaka Ohsawa,¹¹ Yoshihide Sunada,¹¹ Keiko Imamura,¹ Naohiro Egawa,¹ Naoki Yahata,^{1,7} Keisuke Okita,¹ Kazutoshi Takahashi,¹ Isao Asaka,¹ Takashi Aoi,¹ Akira Watanabe,¹ Kaori Watanabe,^{7,10} Chie Kadoya,^{7,10} Rie Nakano,^{7,10} Dai Watanabe,³ Kei Maruyama,⁹ Osamu Hori,¹² Satoshi Hibino,¹³ Tominari Choshi,¹³ Tatsutoshi Nakahata,¹ Hiroyuki Hioki,⁴ Takeshi Kaneko,⁴ Motoko Naitoh,⁵ Katsuhiko Yoshikawa,⁵ Satoko Yamawaki,⁵ Shigehiko Suzuki,⁵ Ryuji Hata,¹⁴ Shu-ichi Ueno,¹⁵ Tsuneyoshi Seki,¹⁶ Kazuhiro Kobayashi,¹⁶ Tatsushi Toda,¹⁶ Kazuma Murakami,⁶ Kazuhiro Irie,⁶ William L. Klein,¹⁷ Hiroshi Mori,¹⁸ Takashi Asada,¹⁹ Ryosuke Takahashi,² Nobuhisa Iwata,^{7,10,*} Shinya Yamanaka,^{1,8} and Haruhisa Inoue^{1,7,8,*}

¹Center for iPS Cell Research and Application (CiRA)

²Department of Neurology, Graduate School of Medicine

³Department of Biological Sciences, Graduate School of Medicine and Department of Molecular and Systems Biology, Graduate School of Biostudies

⁴Department of Morphological Brain Science, Graduate School of Medicine

⁵Department of Plastic and Reconstructive Surgery, Graduate School of Medicine

⁶Organic Chemistry in Life Science, Division of Food Science and Biotechnology, Graduate School of Agriculture Kyoto University, Kyoto 606-8507, Japan

⁷Core Research for Evolutional Science and Technology (CREST)

⁸Yamanaka iPS Cell Special Project

Japan Science and Technology Agency (JST), Saitama 332-0012, Japan

⁹Department of Pharmacology, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan

¹⁰Laboratory of Molecular Biology and Biotechnology, Department of Molecular Medicinal Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan

¹¹Department of Neurology, Kawasaki Medical School, Okayama 701-0192, Japan

¹²Department of Neuroanatomy (Biotargeting), Kanazawa University Graduate School of Medical Sciences, Ishikawa 920-8640, Japan

¹³Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima 729-0292, Japan

¹⁴Department of Functional Histology

¹⁵Department of Psychiatry

Ehime University Graduate School of Medicine, Ehime 791-0295, Japan

¹⁶Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan

¹⁷Department of Neurobiology, Northwestern University, Evanston, IL 60208, USA

¹⁸Department of Neuroscience, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan

¹⁹Department of Neuropsychiatry, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8577, Japan

*Correspondence: haruhisa@cira.kyoto-u.ac.jp (H.I.), iwata-n@nagasaki-u.ac.jp (N.I.)

<http://dx.doi.org/10.1016/j.stem.2013.01.009>

SUMMARY

Oligomeric forms of amyloid- β peptide (A β) are thought to play a pivotal role in the pathogenesis of Alzheimer's disease (AD), but the mechanism involved is still unclear. Here, we generated induced pluripotent stem cells (iPSCs) from familial and sporadic AD patients and differentiated them into neural cells. A β oligomers accumulated in iPSC-derived neurons and astrocytes in cells from patients with a familial amyloid precursor protein (APP)-E693 Δ mutation and sporadic AD, leading to endoplasmic reticulum (ER) and oxidative stress. The accumulated A β oligomers were not proteolytically resistant, and docosahexaenoic acid (DHA) treatment alleviated the stress responses in the AD neural cells. Differential manifestation of ER stress and DHA responsiveness may help explain variable clinical

results obtained with the use of DHA treatment and suggests that DHA may in fact be effective for a subset of patients. It also illustrates how patient-specific iPSCs can be useful for analyzing AD pathogenesis and evaluating drugs.

INTRODUCTION

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder. One of the pathological features of AD is the oligomerization and aggregation and accumulation of amyloid- β peptide (A β), forming amyloid plaques in the brain. Cognitive impairment observed in clinical AD is inversely well correlated with the amount of A β oligomers in the soluble fraction rather than the amount of A β fibrils (amyloid plaques) constituting the oligomers (Haass and Selkoe, 2007; Krafft and Klein, 2010). Increasing evidence has shown that A β oligomers extracted from AD model mice or made from synthetic peptides cause






Figure 1. Establishment of Control and AD Patient-Specific iPSCs, and Derivation of Cortical Neurons Producing Aβs from iPSCs

(A) Established iPSCs from both controls and AD patients showed embryonic stem cell-like morphology (Phase) and expressed pluripotent stem cell markers NANOG (red) and TRA1-60 (green). The scale bar represents 200 μm.

(B) Genomic DNA sequences showed the presence of the homozygous genotype for E693 deletion and the heterozygous genotype for V717L mutation on the APP gene only in AD iPSCs.

(C) Estimation of neuronal differentiation from control and AD-iPSCs. After 2 months of differentiation, neurons were immunostained with antibodies against the neuronal marker TUJ1 and the cortical neuron markers TBR1 and SATB2. The scale bar represents 30 μm.

(D) Proportions of TUJ1-, TBR1-, and SATB2-positive cells in control and AD-iPSCs. Data represent mean ± SD (n = 3 per clone).

(E) Aβ40 and Aβ42 secreted from iPSC-derived neural cells into the medium (extracellular Aβ) were measured at 48 hr after the last medium change. Data represent mean ± SD (n = 3 per clone). Levels of Aβ40 and Aβ42 in AD(APP-E693Δ) without β-secretase inhibitor IV (BSI, 1 μM) were significantly lower than those of the others (*, p < 0.006), and the level of Aβ42 and the ratio of Aβ42/Aβ40 in AD(APP-V717L) without BSI were significantly higher than those of the others (legend continued on next page)

neurotoxicity and cognitive impairments *in vitro* and *in vivo* (Walsh et al., 2002; Gong et al., 2003; Lesné et al., 2006), and this was also true in humans (Kuo et al., 1996; Shankar et al., 2008; Noguchi et al., 2009). Therefore, the formation and accumulation of A β oligomers has been presumed to play a central role in the pathogenesis and clinical symptoms of AD. A β s are composed of 38–43 amino acid residues and are generated from the amyloid precursor protein (APP) by β - and γ -secretase-mediated sequential cleavages. A number of mutations linked to familial AD in the APP gene have been identified. Recently, an atypical early-onset familial AD, caused by an E693 Δ mutation of an APP-producing variant A β lacking 22nd Glu was discovered in Japan (Tomiyama et al., 2008). This APP-E693 Δ mutation presents rare, autosomal-recessive mutations of the APP gene related to familial AD. Patients with the mutation show overt early-onset symptoms of AD but lack A β deposition, according to positron emission tomography (PET) scan analysis with a [¹¹C] Pittsburgh compound-B (PiB) radioprobe (Tomiyama et al., 2008; Shimada et al., 2011). The 22nd Glu within the A β sequence has a destabilizing effect on the formation of oligomeric structures because of the electrostatic repulsion between the adjacent side chain of 22nd Glu (Kassler et al., 2010), and the deletion of the amino acid residue leads to the ready formation of A β oligomers *in vitro* (Nishitsuji et al., 2009). APP-E693 Δ transgenic mice show AD-like pathology, including intracellular oligomer accumulation, but lack extracellular amyloid plaque formation (Tomiyama et al., 2010). However, it remains unclear whether A β oligomers are accumulated in familial and sporadic AD patient neural cells and how intracellular A β oligomers play a pathological role. The compound and/or drugs that might rescue the A β oligomer-induced pathological phenotypes are also unclear. Recent developments in induced pluripotent stem cell (iPSC) technology have facilitated the investigation of phenotypes of patient neural cells *in vitro* and have helped to overcome the lack of success in modeling sporadic AD.

Here, we report the derivation and neuronal and astroglial differentiation of iPSCs from a familial AD patient with an APP-E693 Δ mutation, a familial case with another APP mutation, as well as other sporadic cases. Using patient neurons and astrocytes, we addressed the accumulation and possible pathological roles of intracellular A β oligomers in familial and sporadic AD. We found that A β oligomers were not proteolytically resistant and that docosahexaenoic acid (DHA) treatment attenuated cellular phenotypes of AD neural cells with intracellular A β oligomers in both familial and sporadic AD patients.

RESULTS

iPSC Generation and Cortical-Neuronal Differentiation

Dermal fibroblasts were reprogrammed by episomal vectors (Okita et al., 2011). Control iPSC lines from three unrelated indi-

viduals, three and two familial AD iPSC lines from patients with E693 Δ [AD(APP-E693 Δ)] and V717L[AD(APP-V717L)] APP mutations, respectively, and two sporadic iPSC lines (AD3E211 and AD8K213) from two unrelated patients (Figure S1A available online) were generated (Figures 1A, 1B, and S1B–S1H). To characterize cortical neurons derived from the iPSC lines, we established differentiation methods for cortical neurons by modifying previous procedures (Morizane et al., 2011) (Figure S1I). The differentiated cells expressed the cortical neuron subtype markers SATB2 and TBR1 (Figure 1C), and the differentiated neurons were functionally active (Figures S1J and S1K). There was no prominent difference in the differentiation propensity between control and AD neurons (Figures 1D and S1L).

We analyzed the amounts of extra- and intracellular A β 40 and A β 42 (Figures 1E and 1F). As expected, both A β species were strongly decreased in all cloned AD(APP-E693 Δ) neural cells in comparison to those in control neural cells. In familial AD(APP-V717L) neural cells, an increase in the extracellular A β 42 level and a corresponding decrease in the intracellular A β 42 level were observed, and the A β 42/A β 40 ratio in the culture medium was increased up to 1.5-fold, suggesting that the abnormality of APP metabolism in AD is dependent on the mutation sites in APP. Extracellular A β levels in sporadic AD neural cells were not changed in comparison to those in control neural cells, but intracellular A β in sporadic AD8K213 neural cells apparently decreased (that is, below the detection limit). APP expression levels in the AD(APP-E693 Δ) neural cells were lower than in the others, but the levels of α - and β -secretase-mediated APP processing remained unaltered in all neural cells (Figures 1G, S1M, and S1N). Soluble APP β production was strongly inhibited by treatment with β -secretase inhibitor IV (BSI) (Figure 1G). A β levels in the original fibroblasts and iPSC-derived astrocytes, in which APP expression levels were relatively higher than those in neural cells (data not shown), were lower than those of the corresponding neural cells (Figures S1O and S1P).

Intracellular Accumulation of A β Oligomers in AD(APP-E693 Δ) and in One of the Sporadic AD Neural Cells

Using an immunocytochemical method with the A β -oligomer-specific antibody NU1 (Lambert et al., 2007), we investigated whether AD(APP-E693 Δ) neural cells harbor A β oligomers or not. We found that A β oligomers were accumulated as puncta in the neurons of AD(APP-E693 Δ) and in one of the sporadic AD cases (Figure 2A). The area of A β -oligomer-positive puncta was significantly increased in AD(APP-E693 Δ) neuronal cells relative to control neuronal cells (Figure 2B). Dot blot analysis using cell lysates revealed that A β oligomers were markedly elevated in the AD(APP-E693 Δ) and sporadic AD8K213 neural cells (Figures 2C and 2D), whereas A β oligomers were not detected in the culture medium (data not shown). Another antibody against A β , 11A1, which detects low-molecular-weight oligomers rather than the A β monomer (Murakami et al., 2010), showed results similar to those observed with NU1 (Figures

(*), $p < 0.001$). There are significant differences between dimethyl sulfoxide (DMSO)-control and BSI treatment in each case (*, $p < 0.001$) except that of AD(APP-E693 Δ) for A β 42.

(F) A β 40 and A β 42 in cell lysates (intracellular A β). N.D., not detected. Data represent mean \pm SD ($n = 3$ per clone).

(G) The amount of soluble APP β was not altered in control and AD. Data represent mean \pm SD ($n = 3$ per clone).

See also Figure S1.

S2A–S2D). However, A β oligomers were not detected in cell lysates from the fibroblasts that generate iPSC lines (Figure S2E). To confirm whether A β oligomers were derived from mutant APP(E693 Δ), we transduced a lentiviral vector driven by an EF1 α promoter to overexpress wild or mutant APP(E693 Δ) in control iPSC-derived neural cells and found that A β oligomers emerged inside control neural cells overexpressing mutant APP(E693 Δ) (Figure S2F).

To investigate the intracellular accumulation of A β oligomers in astrocytes derived from control and AD iPSCs, we established an astrocyte-enrichment culture by modifying the method previously reported (Krencik et al., 2011) (Figures S2G–S2J). Dot blot analysis using A β oligomer antibodies revealed that the astrocytes of AD(APP-E693 Δ) and one of the sporadic AD iPSCs accumulated A β oligomers intracellularly (Figures 2E, S2K, and S2L), which was compatible with the results of neurons. On the other hand, we detected no difference in the uptake of extracellular glutamate between control and AD astrocytes (Figure S2M).

A β oligomers were also detected as a protein band with a molecular mass of 50–60 kDa by western blot analysis (Figures 2F and S2N). The accumulation of A β oligomers was inhibited by treatment with BSI (Figures 2A–2G, S2A–S2D, and S2N). To clarify whether the E693 Δ mutation results in accelerated A β oligomerization and/or in a proteolytically resistant and stable form of A β oligomers, we analyzed the levels of A β oligomers over a course of time after BSI treatment. Intracellular A β oligomers started to disappear from 2 hr after the treatment with BSI, almost reaching the control level by 8 hr (Figures 2G and 2H). Secretion of A β 40 from control neural cells was already inhibited at 2 hr after BSI treatment, but the secretion from AD neural cells was under the detection limit in both the presence and absence of BSI (Figure 2I).

Cellular Stress Responses Caused By Intracellular A β Oligomers in AD iPSC-Derived Neural Cells

Extracellular A β deposition in patient brains carrying APP with an E693 Δ mutation is predicted to be extremely low, as amyloid PET imaging with a [11 C] PIB probe revealed a far lower signal in the patients than those observed in sporadic AD brains (Tomiyama et al., 2008). Given that processing by β - and γ -secretases largely proceeds within vesicular endosomal compartments, it was possible that A β oligomers were associated with specific organelles. We characterized the A β oligomer-positive punctate structures in AD(APP-E693 Δ) neural cells and astrocytes by coimmunostaining with antibodies for markers of vesicular compartments and subcellular organelles. Subpopulations of A β oligomer-positive puncta in the AD neurons showed positive immunostaining for an endoplasmic reticulum (ER) marker, binding immunoglobulin protein (BiP); an early endosomal marker, early endosome-associated antigen-1 (EEA1); and

a lysosomal marker, lysosomal-associated marker protein 2 (LAMP2) (data not shown).

To uncover molecules that might be implicated in the dysfunction of AD(APP-E693 Δ) neural cells, we analyzed gene expression profiles of control and AD neural cells (Figure 3A and Table S1). Gene ontology analysis revealed that oxidative-stress-related categories, including peroxiredoxin, oxidoreductase, and peroxidase activities, were upregulated in the AD, whereas glycosylation-related categories were downregulated (Figures 3B and 3C and Table S1), suggesting that ER and Golgi function might be perturbed in AD neural cells. Western blot analysis clarified that the amounts of both BiP and cleaved caspase-4 were elevated in the neurons and astrocytes of the AD(APP-E693 Δ) case, and that of BiP in one of the sporadic AD cases, AD8K213, but not in fibroblasts (Figures 3D–3F and S3A–S3F). We also found that BSI treatment not only prevented the increase in A β oligomer-positive puncta area per cell in the context of AD(APP-E693 Δ) lines but also decreased the amount of BiP and cleaved caspase-4 (Figures 3D–3F). *PRDX4*-coding antioxidant protein peroxiredoxin-4 was the most highly upregulated gene (Figure 3C). Western blot analysis confirmed that the amount of peroxiredoxin-4 was increased up to approximately 5- to 7-fold in lysates from AD(APP-E693 Δ) and in one of the sporadic AD cases, AD8K213 neural cells, but not in fibroblasts, and was decreased by the BSI treatment (Figures 3D, 3G, S3A, S3D, S3G, and S3H), indicating that the antioxidant stress response was provoked by A β oligomer formation in AD(APP-E693 Δ) and sporadic AD8K213. To identify pathogenic species evoking oxidative stress in AD(APP-E693 Δ), we visualized reactive oxygen species (ROS) and found that ROS was increased in both neurons and astrocytes in AD(APP-E693 Δ) and AD8K213 (Figures 3H–3J and S3I–S3L). This increase was counteracted by the BSI treatment. These results indicated that intracellular A β oligomers provoked both ER and oxidative stress, and the increase in ROS most likely occurred via a vicious cycle between ER and oxidative stress (Malhotra and Kaufman, 2007).

Alleviation of Intracellular A β Oligomer-Induced Cellular Stress by DHA

We evaluated BSI and three additional drugs that had been reported to improve ER stress or to inhibit ROS generation: (1) DHA (Begum et al., 2012), (2) dibenzoylmethane (DBM14-26) (Takano et al., 2007), and (3) NSC23766 (Lee et al., 2002) (Figures 4 and S4). DHA treatment significantly decreased the protein level of BiP, cleaved caspase-4, and peroxiredoxin-4 in AD (APP-E693 Δ) neural cells (Figures 4A, 4B, S4A, and S4B), and BiP and peroxiredoxin-4 in sporadic AD8K213 (Figures S4C and S4D). Furthermore, DHA treatment also decreased the generation of ROS in AD(APP-E693 Δ) neural cells (Figures 4C and 4D), whereas the amount of A β oligomers in cell lysates

(F) Western blot analysis of control and AD neural cells in the presence or absence of BSI. BSI treatment (1 μ M) disappeared 6E10-positive \approx 55 kDa protein bands in cell lysates of AD(APP-E693 Δ) and sporadic AD(AD8K213) neural cells.

(G) Disappearance of A β oligomers after BSI treatment was analyzed by dot blot analysis with the use of the NU1 antibody. Intracellular A β oligomers started to disappear 2 hr after BSI treatment.

(H) Signals of blots in (G) were quantified. Data represent mean \pm SD (n = 3 per clone). BSI treatment (1 μ M) decreased intracellular A β in AD neural cells and was reduced to 16–23% of vehicle control by 8 hr. Post hoc analysis revealed that the amounts of A β oligomers at 2 hr after BSI treatment were significantly decreased in comparison to those of DMSO control oligomers (*, p < 0.005).

(I) Changes in extracellular A β 40 levels were analyzed in the experimental condition of (G). Data represent mean \pm SD (n = 3 per clone).

See also Figure S2.




Figure 3. Cellular Stress Responses Caused by Intracellular A β Oligomers in Familial AD (APP-E693 Δ) and Sporadic AD (AD8K213) iPSC-Derived Neural Cells

(A) Hierarchical clustering analysis of differentiated neuronal cells and a heatmap of significantly up- and downregulated genes in AD neural cells. The statistically significant cutoff p value is < 0.05 .

(legend continued on next page)

was not altered (Figures S4E–S4G). In contrast, the high concentration of DHA, DBM14-26, or NSC23766 treatment increased the protein level of BiP (Figure S4B). Finally, to confirm the protective effects of DHA in short-term screening, we analyzed the effect on the survival of AD(APP-E693Δ) neural cells. Neuronal cells were labeled with a lentiviral vector expressing synapsin I-promoter-driven EGFP and cultivated in the medium depleted of neurotrophic factors and neural culture supplements mix. The real-time survival rate of AD(APP-E693Δ) neurons was lower than that of normal control neurons; however, DHA treatment for 16 days partially rescued AD(APP-E693Δ) cell viability (Figures 4E–4G). The real-time survival rate of sporadic AD(AD3E211, AD8K213) neurons for 16 days was unchanged (Figures 4E and 4F and Table S2). We confirmed these results through a lactate dehydrogenase (LDH) assay (Figure 4G). The AD(APP-E693Δ) neurons were also vulnerable to oxidative stress by hydrogen peroxide treatment (Figure S4H). Extracellular Aβ levels were not altered in the assay (Figure 4H).

DISCUSSION

The present study shows that neural cells derived from a patient carrying the pathogenic APP-E693Δ mutation and a sporadic AD patient produce intracellular Aβ oligomers, and the use of these neural cells provided an experimental system for addressing whether such oligomers would cause cellular stress and the killing of neurons and how such intracellular Aβ oligomers might contribute to the disease pathogenesis, despite only one patient carrying the E693Δ mutation being available. Our findings also suggest that the possible heterogeneity of familial and sporadic AD stems from phenotypic differences of intracellular Aβ oligomers and suggests the possibility that DHA, a drug that failed in some clinical trials of AD treatment, might be effective in a portion of AD patients.

We demonstrated that Aβ oligomers were formed and accumulated inside AD(APP-E693Δ) and sporadic AD(AD8K213) neurons by immunostaining (Figures 2A and 2B), dot blot analysis (Figures 2C and 2D), and western blot analysis (Figures 2F and S2N). In addition, intracellular accumulation of Aβ oligomers, which has been supposed to be proteolytically resistant, disappeared after treatment with BSI in both AD neurons (Figures 2G and 2H), indicating that AD(APP-E693Δ) and sporadic AD(AD8K213) neurons still seemed to retain a degrading activity toward Aβ oligomers in which proteasomes, auto-

phagosomes, and/or lysosomes may be involved and, thereby, that the pathological property of Aβ oligomers in a part of AD might be completely abrogated. The sporadic AD(AD8K213) neurons may retain a specific cellular environment that permits the formation of Aβ oligomers. Additional studies aimed at identifying the factors causing such an environment are needed.

We observed that the accumulation of Aβ oligomers induced ER and oxidative stress both in AD(APP-E693Δ) and in sporadic AD(AD8K213) neurons, although caspase-4 activation appeared not to accompany sporadic AD, probably because of the lesser extent of ER stress in comparison to AD(APP-E693Δ). Previously, Nishitsuji et al. (2009) reported that accumulated Aβ oligomers in ER provoke ER stress. This result suggests that oligomers represent a self-aggregating state of Aβ. During this process, Aβ generates ROS, which is supported by the fact that Aβ coordinates the metal ions zinc, iron, and copper, which induce the oligomerization of Aβ. Iron and copper then cause the generation of toxic ROS and calcium dysregulation (Barnham et al., 2004), leading to membrane lipid peroxidation and the impairment of the function of a range of membrane-associated proteins (Hensley et al., 1994; Butterfield, 2003), antioxidant factors being thought to protect ER-stress-induced cellular toxicities (Malhotra and Kaufman, 2007).

We found that intracellular Aβ oligomers were accumulated not only in a case of familial AD with APP-E693Δ mutation but also in a sporadic AD case, although only three clones derived from one familial AD patient carrying an APP-E693Δ mutation and two clones from two sporadic AD patients were analyzed in this study because of the limited number of patients. In contrast, in familial AD with the APP-V717L mutation, of which only one case was available, intracellular Aβ oligomers were not detected, but the extracellular Aβ₄₂/Aβ₄₀ ratio, which is increased in mutant presenilin-mediated familial AD, as reported previously (Yagi et al., 2011), was increased, lending support to the notion that AD could be classified into two categories: extracellular Aβ type and intracellular Aβ type. Although it has been supposed that environmental factors and/or the aging process contribute to neurodegenerative diseases, our findings support the idea that a genetic factor might play a role in a part of sporadic AD, a finding that is compatible with a previous report (Israel et al., 2012). However, identifying the genetic factor would require a larger sample size. The sporadic AD case with intracellular Aβ oligomers might correspond to the case without extracellular Aβ₄₀ elevation of Israel et al. (2012). Analysis of neurons

(B) The gene ontology (GO) term list, calculated from the significantly altered gene expression patterns in the microarray analysis of AD versus control neural cells.

(C) Altered expression levels of genes related to peroxidation activity detected by GO analysis. All values were significantly different from that of the control ($p < 0.05$).

(D–G) Western blot analysis of ER stress markers (BiP and caspase-4), peroxiredoxin-4, and a reference protein (β -actin) in the presence or absence of BSI.

(E–G) Densitometric analysis of (D) are shown. Measured values of proteins were normalized by β -actin. Data represent mean \pm SD ($n = 3$ per clone). Levels of BiP (E), cleaved caspase-4 (F), and peroxiredoxin-4 (G) in AD(APP-E693Δ) and sporadic AD(AD8K213) neural cells without BSI were significantly different from those of the other neural cells (**, $p < 0.005$).

(H) Typical images of reactive oxygen species (ROS) staining, detected by HPF or CellROX, in control and AD neural cells with or without BSI treatment. Scale bars represent 30 μ m.

(I and J) Quantitative data of (H), ROS-HPF (I), and ROS-CellROX (J). Each value was shown as a ratio of the HPF-stained or CellROX area (average of random 25 fields per sample) adjusted with DAPI counts. Data represent mean \pm SD ($n = 3$ per clone). ROS-generation levels in AD(APP-E693Δ) and sporadic AD(AD8K213) neural cells were significantly different from those of the others (**, $p < 0.001$). Data represent mean \pm SD ($n = 3$ per clone).

See also Figure S3 and Table S1.




Figure 4. DHA-Alleviated Cellular Stress Caused By Intracellular Aβ Oligomers

(A) Control and AD(APP-E693Δ) neural cells at day 72 were treated with DHA for 48 hr. Then, cells were lysed and subjected to immunoblot analysis (1 μM, 5 μM, and 15 μM of docosahexaenoic acid [DHA]).

(B) Densitometric analysis of (A) is shown. Measured values were normalized by that of β-actin. Data represent mean ± SD (n = 3 per clone). Two-way analysis of variance (ANOVA) showed significant main effects of DHA treatment (BIP, $F_{(3,64)} = 136.712$, $p < 0.001$; cleaved caspase-4, $F_{(3,64)} = 50.855$, $p < 0.001$) with a significant interaction between APP mutation and DHA treatment (BIP, $F_{(3,64)} = 99.658$, $p < 0.001$; cleaved caspase-4, $F_{(3,64)} = 53.005$, $p < 0.001$). Post hoc analysis revealed significant differences between DMSO (control) and DHA treatment (1, 5, and 15 μM) in AD(APP-E693Δ) neural cells (**, $p < 0.001$). Two-way ANOVA for peroxiredoxin-4 showed significant main effects of DHA treatment ($F_{(3,64)} = 16.995$; $p < 0.001$) with a significant interaction between APP mutation and DHA treatment ($F_{(3,64)} = 32.093$; $p < 0.001$). Post hoc analysis revealed significant differences between DMSO-control and DHA treatment (5 and 15 μM) in AD(APP-E693Δ) neural cells (**, $p < 0.001$). In control neural cells, the 5 μM DHA group was significantly different from the other groups (#, $p < 0.005$).

(C) Typical images of ROS-CellROX and Hoechst33342 signals after treatment with vehicle or 5 μM DHA. The scale bar represents 50 μm.

(legend continued on next page)

and astrocytes, as we performed here, from larger numbers of patients might result in the classification of sporadic AD.

To date, the clinical effectiveness of DHA treatment is still controversial (Freund-Levi et al., 2006; Quinn et al., 2010). It is of particular interest that one of two sporadic AD neurons accumulated intracellular A β oligomers and showed cellular phenotypes that could respond to DHA but the other did not, and this result may explain why DHA treatment was effective for some AD patients, those with the intracellular A β oligomer-associated type of AD, although the timing (that is, the stage of disease development) for starting the treatment would be another critical factor. These results may suggest that patient-specific iPSCs provide a chance to re-evaluate the effect of a drug that failed in AD clinical trials, depending on the selection of the patient type. In the present study, the amount of A β oligomers in our culture was not affected by DHA, although it would be effective for reducing cellular stresses, and reducing the oligomerization of A β was also presumed to be a candidate mechanism of DHA treatment (Cole and Frautschy, 2006). These results indicate that therapy with DHA would alleviate symptoms. Furthermore, the data showing that BSI treatment leads to a reduction in ROS formation at a relatively similar level (Figure 2G) in both AD and control cells might indicate an A β oligomer-independent effect, in addition to an A β oligomer-dependent effect, of BSI.

In any event, patient-specific iPSCs would provide disease pathogenesis, irrespective of the disease being in a familial or sporadic form, as well as enable the evaluation of drug and patient classification of AD.

EXPERIMENTAL PROCEDURES

Derivation of Patient-Specific Fibroblasts

Control and AD-derived human dermal fibroblasts (HDFs) were generated from explants of 3 mm dermal biopsies. After 1–2 weeks, fibroblast outgrowths from the explants were passaged.

iPSC Generation

Human complementary DNAs for reprogramming factors were transduced in HDFs with episomal vectors (*SOX2*, *KLF4*, *OCT4*, *L-MYC*, *LIN28*, and small hairpin RNA for p53). Several days after transduction, fibroblasts were harvested and replated on an SNL feeder cell layer. On the following day, the medium was changed to a primate embryonic stem cell medium (ReproCELL, Japan) supplemented with 4 ng/ml basic FGF (Wako Pure Chemicals Indus-

tries, Japan). The medium was changed every other day. iPSC colonies were picked up 30 days after transduction.

Statistical Analysis

All data are shown as mean \pm SD. For comparisons of the mean between two groups, statistical analysis was performed by applying Student's *t* tests after confirming equality between the variances of the groups. When the variances were unequal, Mann-Whitney *U* tests were performed (SigmaPlot 11.2.0, Systat Software, USA). Comparisons of the mean among three groups or more were performed by one-way, two-way, or three-way analysis of variance followed by a post hoc test with the use of Student-Newman-Keuls Method (SigmaPlot 11.2.0). *p* values < 0.05 were considered significant.

ACCESSION NUMBERS

The Gene Expression Omnibus accession numbers for microarray data reported in this paper are GSE43326 (gene-expression comparison between control and AD clones), GSE43382 (gene-expression change along with the astroglial differentiation), and GSE43328 (gene-expression comparison of generated iPSCs).

SUPPLEMENTAL INFORMATION

Supplemental Information contains Supplemental Experimental Procedures, four figures, and two tables and can be found with this article online at <http://dx.doi.org/10.1016/j.stem.2013.01.009>.

ACKNOWLEDGMENTS

We would like to express our sincere gratitude to all our coworkers and collaborators, Mari Ohnuki, Megumi Kumazaki, Mitsuyo Kawada, Fumihiko Adachi, Takako Enami, and Misato Funayama for technical assistance; Nobuya Inagaki and Norio Harada for technical advice; and Kazumi Murai for editing the manuscript. This research was funded in part by a grant from the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) of the Japan Society for the Promotion of Science (JSPS) to S.Y., from the Alzheimer's Association (IIRG-09-132098) to H.M., from the JST Yamanaka iPS Cell Special Project to S.Y. and H.I., from CREST to H.I., H.M., N.I., and T.T., from a Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan to H.I., from a Grant-in-Aid for Scientific Research on Innovative Area "Foundation of Synapse and Neurocircuit Pathology" (22110007) from the Ministry of Education, Culture, Sports, Science and Technology of Japan to H.I. and N.I., and from the Japan Research Foundation for Clinical Pharmacology to H.I. H.I. conceived the project; T.K., N.I., M.A., and H.I. designed the experiments; T.K., N.I., M.A., K.W., C.K., R.N., N.E., N.Y. and K. Tsukita performed the experiments; T.K., N.I., M.A., and H.I. analyzed the data; K.O., I.A., K.M., T.N., K.I., W.L.K., O.H., S.H., and T.C. contributed

(D) Quantitative data of (C) is shown. Each value indicated the ratio of the CellROX-stained area (an average of random 25 fields per sample) adjusted with DAPI counts. Data represent mean \pm SD (*n* = 3 per clone). Two-way ANOVA showed significant main effects of DHA treatment ($F_{(1,32)} = 43.140$; *p* < 0.001) with a significant interaction between the APP mutation and DHA treatment ($F_{(3,32)} = 23.410$; *p* < 0.001). The DHA group in AD(APP-E693 Δ) neural cells was significantly different from the other groups (**, *p* < 0.005).

(E) Real-time survival rate of control and AD neural cells with and without DHA showing cell viability. The numbers of control and AD(APP-E693 Δ) neurons with Synapsin I-promoter-driven EGFP were sequentially imaged (average of 25 random fields per sample) and counted to assess the survival ratio (*n* = 3 per clone). Data represent mean \pm SD (*n* = 3 per clone). In the cell-survival ratio, three-way ANOVA showed significant main effects of the APP mutation ($F_{(1,256)} = 377.611$; *p* < 0.001), DHA treatment ($F_{(1,256)} = 36.117$; *p* < 0.001), and time ($F_{(7,256)} = 65.272$; *p* < 0.001), with significant interactions between the APP mutation and DHA treatment ($F_{(1,256)} = 18.315$; *p* < 0.001), between the APP mutation and time ($F_{(7,256)} = 20.023$; *p* < 0.001), between DHA treatment and time ($F_{(7,256)} = 4.534$; *p* < 0.001), and among all three factors ($F_{(7,256)} = 5.277$; *p* < 0.001). Post hoc analysis revealed that, on day 14 and day 16, AD(APP-E693 Δ) neural cells were more vulnerable in the long culture than control neural cells and that DHA treatment rescued the vulnerability (*, *p* < 0.001).

(F) Typical images of Synapsin::EGFP neurons used in real-time survival assay. The scale bar represents 50 μ m.

(G) Cytotoxicity in neural culture derived from control and AD iPSCs after treatment with DHA (5 μ M) for 16 days. Measured fluorescent lactate dehydrogenase (LDH) release served as a measure of cytotoxicity. Data represent mean \pm SD (*n* = 3 per clone). Two-way ANOVA showed significant main effects of DHA treatment ($F_{(1,32)} = 16.710$; *p* < 0.001) with a significant interaction between APP-E693 Δ mutation and DHA treatment ($F_{(3,32)} = 9.210$; *p* < 0.005). There was a significant difference in AD(APP-E693 Δ) neural cells between the DMSO-control and DHA groups (*, *p* < 0.05).

(H) A β 40 and A β 42 secreted from iPSC-derived neurons into medium (extracellular A β) at day 16 of the long-term culture were measured at 48 hr after the last medium change. Data represent mean \pm SD (*n* = 3 per clone).

See also Figure S4 and Table S2.

reagents, materials and analysis tools; Y.K., Y.O., Y.S., M.N., K.Y., S.Y., S.S., T.A., R.H., and S.U. recruited the patients; R.T., H.M., and S.Y. provided critical reading and scientific discussions; T.S., K.K., T.T., and K. Takahashi performed microarray analysis; T.A. performed karyotyping; A.W. performed bisulfite genomic sequencing; K.I. and D.W. performed electrophysiology; K. Tsukita, T.K., and H.H. produced the lentivirus; H.I., N.I., M.A., and T.K. wrote the paper. The experimental protocols dealing with human or animal subjects were approved by the institutional review board at each institute. S.Y. is a member without salary of the scientific advisory boards of iPierian, iPSC Academia Japan, Megakaryon Corporation, and Retina Institute Japan.

Received: February 27, 2012
Revised: December 22, 2012
Accepted: January 18, 2013
Published: February 21, 2013

REFERENCES

- Barnham, K.J., Masters, C.L., and Bush, A.I. (2004). Neurodegenerative diseases and oxidative stress. *Nat. Rev. Drug Discov.* **3**, 205–214.
- Begum, G., Kintner, D., Liu, Y., Cramer, S.W., and Sun, D. (2012). DHA inhibits ER Ca²⁺ release and ER stress in astrocytes following in vitro ischemia. *J. Neurochem.* **120**, 622–630.
- Butterfield, D.A. (2003). Amyloid β -peptide [1–42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. *Curr. Med. Chem.* **10**, 2651–2659.
- Cole, G.M., and Frautschy, S.A. (2006). Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. *Nutr. Health* **18**, 249–259.
- Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garfinkel, A., Vedin, I., Vessby, B., Wahlund, L.O., and Palmblad, J. (2006). Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. *Arch. Neurol.* **63**, 1402–1408.
- Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A., and Klein, W.L. (2003). Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc. Natl. Acad. Sci. USA* **100**, 10417–10422.
- Haass, C., and Selkoe, D.J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. *Nat. Rev. Mol. Cell Biol.* **8**, 101–112.
- Hensley, K., Carney, J.M., Mattson, M.P., Aksenova, M., Harris, M., Wu, J.F., Floyd, R.A., and Butterfield, D.A. (1994). A model for β -amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. *Proc. Natl. Acad. Sci. USA* **91**, 3270–3274.
- Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nator, K.L., Boscolo, F.S., et al. (2012). Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* **482**, 216–220.
- Kassler, K., Horn, A.H., and Sticht, H. (2010). Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A β 42-amyloid oligomers. *J. Mol. Model.* **16**, 1011–1020.
- Krafft, G.A., and Klein, W.L. (2010). ADDLs and the signaling web that leads to Alzheimer's disease. *Neuropharmacology* **59**, 230–242.
- Krencik, R., Weick, J.P., Liu, Y., Zhang, Z.J., and Zhang, S.C. (2011). Specification of transplantable astroglial subtypes from human pluripotent stem cells. *Nat. Biotechnol.* **29**, 528–534.
- Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J., and Roher, A.E. (1996). Water-soluble A β (N-40, N-42) oligomers in normal and Alzheimer disease brains. *J. Biol. Chem.* **271**, 4077–4081.
- Lambert, M.P., Velasco, P.T., Chang, L., Viola, K.L., Fernandez, S., Lacor, P.N., Khoun, D., Gong, Y., Bigio, E.H., Shaw, P., et al. (2007). Monoclonal antibodies that target pathological assemblies of A β . *J. Neurochem.* **100**, 23–35.
- Lee, M., You, H.J., Cho, S.H., Woo, C.H., Yoo, M.H., Joe, E.H., and Kim, J.H. (2002). Implication of the small GTPase Rac1 in the generation of reactive oxygen species in response to β -amyloid in C6 astroglia cells. *Biochem. J.* **366**, 937–943.
- Lesné, S., Koh, M.T., Kotilinek, L., Kaye, R., Glabe, C.G., Yang, A., Gallagher, M., and Ashe, K.H. (2006). A specific amyloid- β protein assembly in the brain impairs memory. *Nature* **440**, 352–357.
- Malhotra, J.D., and Kaufman, R.J. (2007). Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? *Antioxid. Redox Signal.* **9**, 2277–2293.
- Morizane, A., Doi, D., Kikuchi, T., Nishimura, K., and Takahashi, J. (2011). Small-molecule inhibitors of bone morphogenetic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. *J. Neurosci. Res.* **89**, 117–126.
- Murakami, K., Horikoshi-Sakuraba, Y., Murata, N., Noda, Y., Masuda, Y., Kinoshita, N., Hatsuta, H., Murayama, S., Shirasawa, T., Shimizu, T., and Irie, K. (2010). Monoclonal antibody against the turn of the 42-residue amyloid β -protein at positions 22 and 23. *ACS Chem. Neurosci.* **1**, 747–756.
- Nishitsuji, K., Tomiyama, T., Ishibashi, K., Ito, K., Teraoka, R., Lambert, M.P., Klein, W.L., and Mori, H. (2009). The E693 Δ mutation in amyloid precursor protein increases intracellular accumulation of amyloid β oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. *Am. J. Pathol.* **174**, 957–969.
- Noguchi, A., Matsumura, S., Dezawa, M., Tada, M., Yanazawa, M., Ito, A., Akioka, M., Kikuchi, S., Sato, M., Ideno, S., et al. (2009). Isolation and characterization of patient-derived, toxic, high mass amyloid β -protein (A β) assembly from Alzheimer disease brains. *J. Biol. Chem.* **284**, 32895–32905.
- Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., et al. (2011). A more efficient method to generate integration-free human iPS cells. *Nat. Methods* **8**, 409–412.
- Quinn, J.F., Raman, R., Thomas, R.G., Yurko-Mauro, K., Nelson, E.B., Van Dyck, C., Galvin, J.E., Ermond, J., Jack, C.R., Jr., Weiner, M., et al. (2010). Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* **304**, 1903–1911.
- Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., et al. (2008). Amyloid- β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* **14**, 837–842.
- Shimada, H., Ataka, S., Tomiyama, T., Takechi, H., Mori, H., and Miiki, T. (2011). Clinical course of patients with familial early-onset Alzheimer's disease potentially lacking senile plaques bearing the E693 Δ mutation in amyloid precursor protein. *Dement. Geriatr. Cogn. Disord.* **32**, 45–54.
- Takano, K., Kitao, Y., Tabata, Y., Miura, H., Sato, K., Takuma, K., Yamada, K., Hibino, S., Choshi, T., Iinuma, M., et al. (2007). A dibenzoylmethane derivative protects dopaminergic neurons against both oxidative stress and endoplasmic reticulum stress. *Am. J. Physiol. Cell Physiol.* **293**, C1884–C1894.
- Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., et al. (2008). A new amyloid β variant favoring oligomerization in Alzheimer's-type dementia. *Ann. Neurol.* **63**, 377–387.
- Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010). A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss *in vivo*. *J. Neurosci.* **30**, 4845–4856.
- Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation *in vivo*. *Nature* **416**, 535–539.
- Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., and Suzuki, N. (2011). Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum. Mol. Genet.* **20**, 4530–4539.